GlassScriptPhysician profile
Jean Richard Etienne
NPI 1801806658
$7,624.94
in general payments reported to CMS, 2019-2025
29 companies · $759 in 2025
The $759 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,328 · 2020: $1,074 · 2021: $982 · 2022: $1,205 · 2023: $1,063 · 2024: $1,214 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,019 · Education: $17.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,018.71 |
| Education | $17.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,816.36 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,265.30 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $926.36 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $640.37 | 2021-2025 | |
| Gilead Sciences, INC. | $609.73 | 2019-2025 | Biktarvy |
| Janssen Pharmaceuticals, INC | $288.47 | 2019-2023 | Xarelto |
| Pfizer INC. | $258.00 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $239.54 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $210.19 | 2019-2025 | Pifeltro |
| Abbvie INC. | $180.40 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $177.38 | 2019 | |
| Viiv Healthcare Company | $151.59 | 2022-2025 | Dovato |
| Exact Sciences Corporation | $132.00 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.96 | 2020-2022 | |
| Global Blood Therapeutics, INC. | $88.36 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $78.72 | 2020-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $75.28 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $55.90 | 2021-2025 | Eliquis |
| Angiodynamics, INC. | $44.43 | 2019 | |
| Lundbeck LLC | $44.00 | 2024-2025 | Rexulti |
| Lucid Diagnostics INC. | $29.61 | 2023 | |
| Allergan, INC. | $28.69 | 2020 | |
| Ironshore Pharmaceuticals INC. | $25.67 | 2019 | |
| Redhill Biopharma INC. | $24.23 | 2020 | |
| Phadia US INC. | $23.10 | 2023 | Immunocap |
| Genentech USA, INC. | $22.38 | 2020 | |
| Shield Therapeutics INC | $22.01 | 2023 | Accrufer |
| Otsuka America Pharmaceutical, INC. | $21.42 | 2024 | Rexulti |
| Dexcom, INC. | $20.49 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jean Etienne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.